BerGenBio ASA (BGBIO.OL)
NOK 1.76
(3.9%)
NOK 1.76
(3.9%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 354 Thousand NOK | -21674.29% |
| 2022 | 389 Thousand NOK | -49.74% |
| 2021 | 774 Thousand NOK | 100.87% |
| 2020 | -88.86 Million NOK | -57.71% |
| 2019 | -56.35 Million NOK | 12.17% |
| 2018 | -64.15 Million NOK | -33142.49% |
| 2017 | -193 Thousand NOK | 6.76% |
| 2016 | -207 Thousand NOK | -15.64% |
| 2015 | -179 Thousand NOK | -129.93% |
| 2014 | 598 Thousand NOK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -17.13 Million NOK | -4.2% |
| 2024 Q2 | -105 Thousand NOK | 99.39% |
| 2023 Q3 | -109 Thousand NOK | -1457.14% |
| 2023 Q2 | -7000.00 NOK | 0.0% |
| 2023 FY | -83.92 Million NOK | -21674.29% |
| 2023 Q1 | -7000.00 NOK | -101.8% |
| 2023 Q4 | -16.44 Million NOK | -14982.57% |
| 2022 Q1 | -317 Thousand NOK | -140.96% |
| 2022 FY | 389 Thousand NOK | -49.74% |
| 2022 Q4 | 389 Thousand NOK | 377.86% |
| 2022 Q3 | -140 Thousand NOK | 55.41% |
| 2022 Q2 | -314 Thousand NOK | 0.95% |
| 2021 Q2 | -335 Thousand NOK | 0.0% |
| 2021 Q3 | -335 Thousand NOK | 0.0% |
| 2021 Q4 | 774 Thousand NOK | 331.04% |
| 2021 Q1 | -335 Thousand NOK | -155.74% |
| 2021 FY | 774 Thousand NOK | 100.87% |
| 2020 Q3 | - NOK | 0.0% |
| 2020 Q4 | 601 Thousand NOK | 0.0% |
| 2020 FY | -88.86 Million NOK | -57.71% |
| 2020 Q1 | - NOK | -100.0% |
| 2020 Q2 | - NOK | 0.0% |
| 2019 Q3 | - NOK | 0.0% |
| 2019 FY | -56.35 Million NOK | 12.17% |
| 2019 Q4 | 218 Thousand NOK | 0.0% |
| 2019 Q2 | - NOK | -100.0% |
| 2019 Q1 | 8.68 Million NOK | 271.82% |
| 2018 Q3 | - NOK | 0.0% |
| 2018 Q4 | 2.33 Million NOK | 0.0% |
| 2018 Q2 | - NOK | 0.0% |
| 2018 FY | -64.15 Million NOK | -33142.49% |
| 2018 Q1 | - NOK | 0.0% |
| 2017 Q2 | - NOK | 0.0% |
| 2017 Q1 | - NOK | 0.0% |
| 2017 FY | -193 Thousand NOK | 6.76% |
| 2017 Q3 | - NOK | 0.0% |
| 2017 Q4 | - NOK | 0.0% |
| 2016 FY | -207 Thousand NOK | -15.64% |
| 2016 Q3 | - NOK | 0.0% |
| 2016 Q2 | - NOK | 0.0% |
| 2016 Q4 | - NOK | 0.0% |
| 2015 FY | -179 Thousand NOK | -129.93% |
| 2014 FY | 598 Thousand NOK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arctic Bioscience AS | 9.77 Million NOK | 96.378% |
| Aqua Bio Technology ASA | 607.92 Thousand NOK | 41.769% |
| ArcticZymes Technologies ASA | 113.01 Million NOK | 99.687% |
| Hofseth BioCare ASA | 29.87 Million NOK | 98.815% |
| PCI Biotech Holding ASA | 2.99 Million NOK | 88.161% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | -2.76 Million NOK | 112.789% |